Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Chest
|
January 16, 2003
Confounding issues in COPD risk study?
Ranjeeta Sinvhal, Lorraine Tosiello, Greg Cable
British Journal of Clinical Pharmacology
|
April 28, 2023
Letter to the editor concerning the article: 'Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)'
Ranjeeta Sinvhal, Whitney S Krueger, Ryan D Kilpatrick, et al.
Therapeutic Innovation & Regulatory Science
|
August 10, 2025
Publisher Correction: Leveraging Multi-National Observational Study in Post-Marketing Safety Assessment: Challenges and Strategies
Li-An Lin, Tarek A Hammad, Wei Liu, et al.
Therapeutic Innovation & Regulatory Science
|
August 5, 2025
Leveraging Multi-National Observational Study in Post-Marketing Safety Assessment: Challenges and Strategies
Li-An Lin, Tarek A Hammad, Wei Liu, et al.
Journal of the American Academy of Dermatology
|
February 25, 2021
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data
Neil H Shear, Keith A Betts, Ahmed M Soliman, et al.
Pharmaceutical Medicine
|
December 16, 2025
Publicly Available Clinical Trial Safety Data: Review and a Call for Standardization and Improved Reporting Practices
Barbara A Hendrickson, Cynthia McShea, Tarek A Hammad, et al.
Dermatology and Therapy
|
August 17, 2024
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials
Kenneth B Gordon, Andrew Blauvelt, Hervé Bachelez, et al.
Dermatology and Therapy
|
October 2, 2024
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis
Andrew F Alexis, Melinda Gooderham, Shawn G Kwatra, et al.
Journal of the American Academy of Dermatology
|
August 8, 2023
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up
Kim A Papp, Andrew Blauvelt, Lluís Puig, et al.
Anais Brasileiros De Dermatologia
|
December 8, 2024
Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil
Tania F Cestari, Cacilda da Silva Souza, Luna Azulay-Abulafia, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Chest
|
January 16, 2003
Confounding issues in COPD risk study?
Ranjeeta Sinvhal, Lorraine Tosiello, Greg Cable
British Journal of Clinical Pharmacology
|
April 28, 2023
Letter to the editor concerning the article: 'Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)'
Ranjeeta Sinvhal, Whitney S Krueger, Ryan D Kilpatrick, et al.
Therapeutic Innovation & Regulatory Science
|
August 10, 2025
Publisher Correction: Leveraging Multi-National Observational Study in Post-Marketing Safety Assessment: Challenges and Strategies
Li-An Lin, Tarek A Hammad, Wei Liu, et al.
Therapeutic Innovation & Regulatory Science
|
August 5, 2025
Leveraging Multi-National Observational Study in Post-Marketing Safety Assessment: Challenges and Strategies
Li-An Lin, Tarek A Hammad, Wei Liu, et al.
Journal of the American Academy of Dermatology
|
February 25, 2021
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data
Neil H Shear, Keith A Betts, Ahmed M Soliman, et al.
Pharmaceutical Medicine
|
December 16, 2025
Publicly Available Clinical Trial Safety Data: Review and a Call for Standardization and Improved Reporting Practices
Barbara A Hendrickson, Cynthia McShea, Tarek A Hammad, et al.
Dermatology and Therapy
|
August 17, 2024
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials
Kenneth B Gordon, Andrew Blauvelt, Hervé Bachelez, et al.
Dermatology and Therapy
|
October 2, 2024
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis
Andrew F Alexis, Melinda Gooderham, Shawn G Kwatra, et al.
Journal of the American Academy of Dermatology
|
August 8, 2023
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up
Kim A Papp, Andrew Blauvelt, Lluís Puig, et al.
Anais Brasileiros De Dermatologia
|
December 8, 2024
Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil
Tania F Cestari, Cacilda da Silva Souza, Luna Azulay-Abulafia, et al.
Page
of 1